Analysis of pharmacokinetics and pharmacodynamics for capecitabine during new chemotherapy regimen by bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancer

Not Applicable

• Conditions: unresectable colorectal cancer

• Registration Number: JPRN-UMIN000013038
• Lead Sponsor: Tsukasa Hotta

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-02-01
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1.Treatment for ascites and thoracic effusion is needed. 2.There is brain tumor or brain metastasis. 3.Untreated double cancer within 5 years 4.There is cerebrovascular disease 5.surgery within 4 weeks 6.surgery for study 7.use of drug effected for blood coagulation system 8.Bleeding tendency 9.Uncontrorable peptic ulcer 10.gastrointestinal perforation within 6 months 11.untreated fructure 12.renal failure 13.Uncontrorable hypertension 14.Uncontrorable diabetes meritus 15.heart disease 16.hypersensitivity for fluorouracil and platinum 17.DPD defect 18.Uncontrorable diarrhea 19.interstitial pneumonia or pulmonary fibrosis 20.organ transplant needed immunosuppressant drug 21.Uncontrorable infectious disease 22.similarterm for BV treatment 23.difficult for oral intake

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Confirmation for PK/PD analysis of capecitabine